Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling

BACKGROUND: The FDA-approved small-molecule drug dasatinib is currently used as a treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on microglial and/or astrocytic neuroinflammatory responses and its mechanism of action have not been studied in detail. METHODS: BV2 micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Ka-Young, Lee, Hyun-ju, Woo, Hanwoong, Kang, Ri-Jin, Han, Kyung-Min, Park, HyunHee, Lee, Sang Min, Lee, Ju-Young, Jeong, Yoo Joo, Nam, Hyun-Wook, Nam, Youngpyo, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815018/
https://www.ncbi.nlm.nih.gov/pubmed/31655606
http://dx.doi.org/10.1186/s12974-019-1561-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815018/
https://www.ncbi.nlm.nih.gov/pubmed/31655606
http://dx.doi.org/10.1186/s12974-019-1561-x

Ejemplares similares